Shots: The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any […]readmore
Tags : Dengue
Shots: The approval follows three studies assessing Dengvaxia vs PBO in 35,000 patients with 9 through 16 years of age with laboratory-confirmed dengue caused by serotypes 1–4 living in dengue-endemic […]readmore
Shots: The P-III TIDES study contains three parts assessing TAK-003 (0.5ml, SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of […]readmore